To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Zomaril Reduces Symptoms Of Schizophrenia And Schizoaffective Disorder URL: http://www.pslgroup.com/dg/14D45A.htm Doctor's Guide December 2, 1999
SOUTH SAN FRANCISCO, CA -- December 2, 1999 -- Titan Pharmaceuticals announced encouraging results from preliminary analysis of study ILP3000, the first large scale, controlled Phase III study of the safety and efficacy of the investigational drug Zomaril (iloperidone) in the treatment of schizophrenia. ILP3000 included approximately 600 patients treated at 40 sites across the United States and was designed to assess the safety of Zomaril ™ and its effect on positive and negative symptoms in schizoaffective and schizophrenic patients. Zomaril, which has an antagonistic activity on a wide spectrum of brain receptors for dopamine and serotonin, with preferential affinity for 5HT2A serotonin receptors in humans, had previously shown activity against both positive and negative symptoms of schizophrenia, as well as a low liability for inducing extrapyramidal symptoms (movement disorders) in Phase II clinical trials. Analysis of the ILP3000 results indicates that Zomaril statistically significantly reduced the symptoms of schizophrenia and schizoaffective disorder as measured by the Brief Psychiatric Rating Scale (BPRS) and confirmed the excellent tolerability profile, including the lack of extrapyramidal symptoms. "We are encouraged by the results of this initial study," stated Dr. Joerg Reinhardt, head of Novartis Pharma Development. "We are well on track in our development of Zomaril as a novel, potential first line therapy for schizophrenia and psychotic disorders." Titan's CEO, Dr. Louis R. Bucalo, called these initial results very promising and noted, "We are very pleased to see that the global Phase III program conducted by Novartis is confirming earlier Phase II studies with Zomaril. Despite decades of progress, clinicians still lack an optimal therapy for patients with schizophrenia. We are hopeful that Zomaril will represent that next significant leap forward." In November 1997 Novartis Pharma AG entered into an agreement with Titan Pharmaceuticals for the worldwide development, manufacturing, and marketing, excluding Japan, of Titan's proprietary product iloperidone (Zomaril). Related Link: Novartis Pharma AG. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.